Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Expands in Emerging Markets, Established Products

This article was originally published in The Pink Sheet Daily

Executive Summary

By licensing in dozens of generics, the company aims to strengthen both its geographic and product diversity.

You may also be interested in...



Another Busy Year of Drug Recalls Led to Shortages of Injectables

Manufacturers recalled more drug products from the U.S. market in 2010 than they had in any year but 2009.

Another Busy Year of Drug Recalls Led to Shortages of Injectables

Manufacturers recalled more drug products from the U.S. market in 2010 than they had in any year but 2009.

Pfizer, Biocon Brush Off Deal Talks As Speculative, But Is There Fire Behind The Smoke?

MUMBAI - Possibilities of a collaborative deal between Pfizer and Biocon have been dismissed as highly speculative by both companies for the last few weeks but going by the latest indications, the two could well be on course to joining forces for a few "significant projects.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069454

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel